Lexeo Therapeutics (LXEO) Competitors $1.82 +0.03 (+1.68%) Closing price 04/8/2025 04:00 PM EasternExtended Trading$1.77 -0.05 (-2.97%) As of 04/8/2025 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LXEO vs. AKBA, RLAY, CGEM, MNMD, PGEN, PHAT, KROS, AUTL, VERV, and ZVRAShould you be buying Lexeo Therapeutics stock or one of its competitors? The main competitors of Lexeo Therapeutics include Akebia Therapeutics (AKBA), Relay Therapeutics (RLAY), Cullinan Therapeutics (CGEM), Mind Medicine (MindMed) (MNMD), Precigen (PGEN), Phathom Pharmaceuticals (PHAT), Keros Therapeutics (KROS), Autolus Therapeutics (AUTL), Verve Therapeutics (VERV), and Zevra Therapeutics (ZVRA). These companies are all part of the "pharmaceutical products" industry. Lexeo Therapeutics vs. Akebia Therapeutics Relay Therapeutics Cullinan Therapeutics Mind Medicine (MindMed) Precigen Phathom Pharmaceuticals Keros Therapeutics Autolus Therapeutics Verve Therapeutics Zevra Therapeutics Lexeo Therapeutics (NASDAQ:LXEO) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation, community ranking and profitability. Does the MarketBeat Community believe in LXEO or AKBA? Akebia Therapeutics received 394 more outperform votes than Lexeo Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Lexeo Therapeutics an outperform vote while only 63.25% of users gave Akebia Therapeutics an outperform vote. CompanyUnderperformOutperformLexeo TherapeuticsOutperform Votes26100.00% Underperform VotesNo VotesAkebia TherapeuticsOutperform Votes42063.25% Underperform Votes24436.75% Does the media favor LXEO or AKBA? In the previous week, Akebia Therapeutics had 3 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 12 mentions for Akebia Therapeutics and 9 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.74 beat Akebia Therapeutics' score of 0.42 indicating that Lexeo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexeo Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Akebia Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, LXEO or AKBA? Lexeo Therapeutics has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500. Comparatively, Akebia Therapeutics has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500. Do analysts rate LXEO or AKBA? Lexeo Therapeutics presently has a consensus target price of $22.20, suggesting a potential upside of 1,119.78%. Akebia Therapeutics has a consensus target price of $6.50, suggesting a potential upside of 286.90%. Given Lexeo Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Lexeo Therapeutics is more favorable than Akebia Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexeo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Akebia Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is LXEO or AKBA more profitable? Lexeo Therapeutics has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -27.07%. Akebia Therapeutics' return on equity of 0.00% beat Lexeo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Lexeo TherapeuticsN/A -57.66% -48.18% Akebia Therapeutics -27.07%N/A -20.57% Do insiders & institutionals have more ownership in LXEO or AKBA? 60.7% of Lexeo Therapeutics shares are owned by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are owned by institutional investors. 4.5% of Lexeo Therapeutics shares are owned by insiders. Comparatively, 4.1% of Akebia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has stronger earnings and valuation, LXEO or AKBA? Akebia Therapeutics has higher revenue and earnings than Lexeo Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLexeo Therapeutics$650K92.95-$66.39M-$3.08-0.59Akebia Therapeutics$160.18M2.48-$51.92M-$0.33-5.09 SummaryLexeo Therapeutics beats Akebia Therapeutics on 12 of the 19 factors compared between the two stocks. Remove Ads Get Lexeo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LXEO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LXEO vs. The Competition Export to ExcelMetricLexeo TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$60.42M$2.70B$5.08B$6.91BDividend YieldN/A1.52%5.33%4.20%P/E Ratio-0.5828.5321.3317.05Price / Sales92.95402.11349.5885.95Price / CashN/A168.6838.1534.64Price / Book0.433.296.053.66Net Income-$66.39M-$72.06M$3.19B$247.27M7 Day Performance-41.85%-10.41%-7.80%-8.86%1 Month Performance-32.59%-25.24%-6.79%-12.84%1 Year Performance-86.17%-36.94%0.32%-10.80% Lexeo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LXEOLexeo Therapeutics2.9612 of 5 stars$1.82+1.7%$22.20+1,119.8%-86.2%$60.42M$650,000.00-0.5858Analyst ForecastNews CoverageGap UpHigh Trading VolumeAKBAAkebia Therapeutics3.4621 of 5 stars$1.92+0.5%$6.75+251.6%+9.8%$453.56M$160.18M-8.35430RLAYRelay Therapeutics2.2273 of 5 stars$2.62-3.7%$19.80+655.7%-72.2%$444.15M$10.01M-1.00330CGEMCullinan Therapeutics1.915 of 5 stars$7.57-5.6%$32.86+334.0%-56.9%$442.94MN/A-2.6730News CoveragePositive NewsMNMDMind Medicine (MindMed)1.4521 of 5 stars$5.85-5.5%$25.11+329.2%-55.1%$440.90MN/A-2.5940Gap UpPGENPrecigen2.9203 of 5 stars$1.49-6.3%$7.00+369.8%-17.0%$438.12M$3.93M-2.71190Gap DownPHATPhathom Pharmaceuticals2.9728 of 5 stars$6.27-5.0%$22.17+253.5%-61.7%$436.62M$55.25M-1.10110KROSKeros Therapeutics3.5458 of 5 stars$10.19-5.6%$42.33+315.4%-84.6%$413.33M$3.55M-1.96100Positive NewsGap DownHigh Trading VolumeAUTLAutolus Therapeutics2.1289 of 5 stars$1.55-6.6%$9.52+514.2%-78.3%$412.45M$10.12M-1.28330Gap UpVERVVerve Therapeutics2.0188 of 5 stars$4.57-12.5%$25.50+458.0%-64.6%$405.80M$32.33M-1.86110Gap UpZVRAZevra Therapeutics2.3538 of 5 stars$7.49-4.6%$22.29+197.5%+33.4%$405.33M$23.61M-3.8020Gap Up Remove Ads Related Companies and Tools Related Companies Akebia Therapeutics Competitors Relay Therapeutics Competitors Cullinan Therapeutics Competitors Mind Medicine (MindMed) Competitors Precigen Competitors Phathom Pharmaceuticals Competitors Keros Therapeutics Competitors Autolus Therapeutics Competitors Verve Therapeutics Competitors Zevra Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LXEO) was last updated on 4/9/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredElon’s Silver Play? Trump Clears the PathNothing is confirmed—yet. But Musk has disrupted every industry he's touched, and Trump's policies make the ti...Priority Gold | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexeo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexeo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
